evipedia.ai
← Back

Tesamorelin for Health & Longevity

Created on 10/28/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Tesamorelin, a prescription injection approved to shrink deep abdominal fat from antiviral treatment, prompts the body's own growth hormone release. Fat loss is well supported; benefits for liver fat, blood fats, artery walls and older adults' thinking have moderate support. Skin reactions, swelling and joint pain are common; blood sugar rises in some users. Benefits fade after stopping, requiring ongoing injections and blood tests. Value for healthy adults remains uncertain. (Full Review)

Protocol

Approved dose (Egrifta WR)
1.28 mg once daily
Subcutaneous injection in the abdomen; one vial reconstituted weekly; formulations are not substitutable
Lower-dose regimen in older adults
1 mg nightly
30 minutes before bedtime, for 20 weeks, used in the cognition trial
Time of day
The label sets no time
Bedtime dosing aligns with the natural nighttime growth hormone pulse; morning dosing is also common
Time to effect
Visceral fat
26 weeks
When reduction was assessed; IGF-1 rises within weeks
Liver fat
6 to 12 months
When change was assessed
Cognitive change
10 to 20 weeks
When change was assessed

Benefits

Contraindications
  • Disrupted hypothalamic-pituitary axis (pituitary removal or underactivity, pituitary tumor or surgery, head irradiation or head trauma)
  • Active malignancy (prior cancer must be inactive with treatment complete)
  • Pregnancy
  • Known hypersensitivity to tesamorelin or its excipients (mannitol, hydroxypropyl betadex)
  • Breastfeeding
  • Children and adolescents with open growth plates
  • Acute critical illness (after open-heart or abdominal surgery, multiple trauma, acute respiratory failure)
  • Persistent IGF-1 above +3 SDS
  • Active proliferative diabetic retinopathy
    •
Key Interactions
  • Drugs cleared by CYP450 liver enzymes (corticosteroids, sex steroids, anticonvulsants, cyclosporine)
  • Glucocorticoid replacement (hydrocortisone, cortisone acetate, prednisone)
  • Glucose-lowering drugs (metformin, glipizide, insulin)
    •
Theoretical (inferred from mechanism)
  • Injected GH (somatropin) and GH secretagogues (e.g., CJC-1295, ibutamoren)
  • Oral estrogen (oral contraceptives, oral estradiol)
  • Somatostatin analogues (octreotide, lanreotide)
  • GLP-1 receptor agonists (e.g., semaglutide, tirzepatide)
  • Over-the-counter NSAIDs (e.g., ibuprofen, naproxen)
  • Over-the-counter high-dose niacin (1 g or more daily)
  • Supplements marketed to raise GH (e.g., arginine, alpha-GPC)
  • Fish oil (omega-3 fatty acids)
  • Testosterone therapy
    •

Risk & Side Effects

  • High: Injection-site reactions; Fluid retention, joint and muscle pain, and nerve symptoms
    •
  • Medium: Glucose intolerance and new-onset diabetes; Hypersensitivity reactions and anti-drug antibodies
    •
  • Low: Growth of existing or undetected cancers; Higher mortality during acute critical illness
    •
  • Speculative: Worsening diabetic retinopathy; Fetal harm in pregnancy; Faster biological aging from GH-axis stimulation
    •

Monitoring

Marker Target Why
IGF-1 Within the age-specific range; consider stopping if persistently above +3 SDS Confirms response, flags excess
HbA1c Below 5.7% Safety check: rise toward 6.5% changes use
Fasting glucose Below 100 mg/dL Early rises signal intolerance
Triglycerides Below 150 mg/dL Falls in responders
Visceral fat (DXA or MRI) Below 140 cm² Primary response marker
Waist circumference Below 102 cm in men and 88 cm in women Low-cost response proxy
Liver fat fraction (MRI or spectroscopy) Below 5% Response in people with fatty liver

Cadence: Baseline before the first injection; fasting glucose at 2 to 4 weeks; IGF-1, HbA1c and lipids at 3 months; waist and visceral fat at 6 months, liver fat at 6 to 12 months; then glucose, HbA1c and IGF-1 every 6 months, with symptom review at each visit

Qualitative Assessment

  • Joint pain, swelling of hands or ankles, and hand numbness or tingling
  • Injection-site redness, itching or bruising
  • Belt size and abdominal appearance
  • Energy, sleep quality and subjective mental sharpness
  • Thirst or frequent urination
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.